Novartis has started a strategic review of its Sandoz generics division following a further sales decline in the third quarter. Sandoz’s sales were down by 1% in the quarter on weak retail demand and price competition for its generic medicines and biosimilars. Announcing the review on 26 October, the company said “options range from retaining the business to separation.”
